Belharra Therapeutics is a privately held drug discovery company that is disrupting the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform. Belharra scientists can identify small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type using its chemoproteomics